Home 
Find my MSL
Vaccine Stability Calculator
REPORT SUSPECTED ADVERSE REACTIONS 
Pipeline
At GSK, our pipeline is focused on unlocking the science of the immune system, human genetics, and advanced technologies to develop vaccines and specialty medicines.
Our products in development progress through three stages: phase I, phase II, and phase III/registrational. Each of these phases allows us to assess the safety and efficacy of our investigational products to eventually provide data to support applications for regulatory approval.
DISEASE STATES
VCRC-VPPRN EGPA Registry (Observational Study)
VCRC-VPPRN EGPA Registry (Observational Study)
Anti-BLyS (Belimumab)
SABLE: Safety and Effectiveness of Belimumab in Systemic Lupus Erythematosus Registry
A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) (BE-EARLY)
Anti-BLyS (Belimumab)
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease (BLISSc-ILD)
Anti-BLyS (Belimumab)
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease (BEconneCTD-ILD)
Anti-BLyS (Belimumab)
Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN (OBSErve-LN)
0 results - Use filter to search Pipeline
Disclaimer
This document contains information for healthcare providers and is intended solely for educational purposes. This display includes ongoing clinical trials for both approved and investigational compounds.
Some agents are approved in select indications. Inclusion in this display does not imply regulatory approval for these compounds or all indications. Information about all trials can be found at www.clinicaltrials.gov.
